The Methodist Hospital in Houston, Texas, an affiliate of Weill Cornell Medical College of Cornell University, offers an ACGME-accredited hematopathology fellowship and an ACGME-accredited selective hematopathology fellowship to provide broad exposure to the evaluation of hematopathological diseases and the technology used to ensure accurate diagnoses. Located in the heart of the Texas Medical Center, The Methodist Hospital is a 950-bed private adult teaching hospital with a 1.6 million square foot outpatient center that registers over 310,000 annual outpatient visits. The hospital offers a full range of services from primary to tertiary care, including a multi-organ transplant center and cancer center that includes a center for cell and gene therapy.
Two one-year fellowship positions in hematopathology are available each academic year for physicians interested in board certification and pursuing a professional career in hematopathology. Training will include experience in bone marrow and lymph node pathology, immunophenotyping by flow cytometry and immunohistochemistry, molecular diagnostics, coagulation and other areas of laboratory hematology. The program includes a cytogenetics rotation at The University of Texas M.D. Anderson Cancer Center and a pediatric hematology rotation at Memorial Hermann Hospital and Texas Children's Hospital. Fellows present case conferences and teach pathology residents, medical students and clinical fellows. Laboratory management and administrative experience during the program also provide the fellows with an adequate background to understand the organization and operation of a hematopathology laboratory.
Two one-year fellowship positions in selective hematopathology are also available each academic year for physicians interested in an academic career in hematopathology. Training will focus on technical and research applications in the areas of immunophenotyping by flow cytometry, immunohistochemistry, molecular diagnostics, and cytogenetics. There are specific rotations in cytogenetics, molecular genetics, and flow cytometry. Near the end of the fellowship, the fellows will also rotate through a clinical service for review of bone marrow and lymph node histopathology. Note: This selective hematopathology fellowship does not confer board eligibility in hematopathology.
For both fellowships, it is anticipated that an area of research interest will be identified early in the fellowship and that one or more clinical research projects will be completed during the training. State-of-the-art technologies, such as cDNA microarray, next generation sequencing, 8-color flow cytometry, and fluorescence-activated cell sorting are available for fellows interested in pursuing an academic career. Both fellowships are directed by Chung-Che "Jeff" Chang, M.D., Ph.D., a board certified hematopathologist with subspecialty interest in myeloma, diffuse large B-cell lymphoma and myedysplastic syndromes. The fellowships are also supervised by five additional pathologists with subspecialty certification in hematopathology, two pathologists with subspecialty certification in molecular genetics, and a pathologist with subspecialty certification in transfusion medicine.
Candidates must be board certified or board eligible in anatomic and/or clinical pathology. Candidates must hold or be eligible for a Texas Physician In Training Permit or Licensure.
Commensurate with level of post-graduate training.
Application deadline is 18 months prior to the intended fellowship year which begins July 1.
Application inquiries are to be directed to:
April Ewton, M.D.
Director, Hematopathology Fellowship
Department of Pathology and Genomic Medicine
The Methodist Hospital
6565 Fannin Street, M227
Houston, TX 77030